Prana Biotechnology Limited researches and develops therapeutic drugs for the treatment of Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidates include PBT434 that is in Phase I clinical trial for the treatment for Parkinson's disease and other movement disorders; and PBT2, which has completed four Phase I studies and a Phase IIa clinical trial for patients with Alzheimer's disease. It also completed the IMAGINE Phase II biomarker imaging trial in Alzheimer's disease; and a open label IMAGINE Extension study and the Reach2HD Phase IIa trial in Huntington disease. The company was founded in 1997 and is based in Melbourne, Australia.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAN
Previous Symbol
CUSIPN/A
Phone61-3-9349-4906
Debt
Debt-to-Equity RatioN/A
Current Ratio7.09
Quick Ratio7.09
Price-To-Earnings
Trailing P/E Ratio-2.00
Forward P/E Ratio-1.79
P/E GrowthN/A
Sales & Book Value
Annual Sales$150,000.00
Price / Sales83.07
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.40 per share
Price / Book1.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees14
Outstanding Shares8,900,000
Market Cap$11.83 million
OptionableNot Optionable
Prana Biotechnology (NASDAQ:PRAN) Frequently Asked Questions
What is Prana Biotechnology's stock symbol?
Prana Biotechnology trades on the NASDAQ under the ticker symbol "PRAN."
What price target have analysts set for PRAN?
1 brokers have issued 12 month price targets for Prana Biotechnology's stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate Prana Biotechnology's share price to reach $4.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View Analyst Price Targets for Prana Biotechnology.
What is the consensus analysts' recommendation for Prana Biotechnology?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prana Biotechnology in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prana Biotechnology.
Has Prana Biotechnology been receiving favorable news coverage?
News headlines about PRAN stock have trended somewhat positive this week, InfoTrie reports. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prana Biotechnology earned a coverage optimism score of 1.0 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 9.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the next few days.
Who are some of Prana Biotechnology's key competitors?
Some companies that are related to Prana Biotechnology include Conatus Pharmaceuticals (CNAT), Forward Pharma A/S (FWP), Aptevo Therapeutics (APVO), Nemus Bioscience (NMUS), Evoke Pharma (EVOK), Catabasis Pharmaceuticals (CATB), DiaMedica Therapeutics (DMCAF), Zosano Pharma (ZSAN), Leap Therapeutics (LPTX), Vascular Biogenics (VBLT), Clearside Biomedical (CLSD), GT Biopharma (GTBP), ProPhase Labs (PRPH), Helix Biopharma (HBPCF) and Novan (NOVN).
Who are Prana Biotechnology's key executives?
Prana Biotechnology's management team includes the folowing people:
- Mr. Geoffrey Paul Kempler, Co-Founder, Exec. Chairman, CEO & MD (Age 63)
- Ms. Kathryn Andrews B.Com, CPA, Chief Financial Officer (Age 51)
- Dr. David A. Stamler M.D., Chief Medical Officer, Sr. VP of Clinical Devel. and Member of R&D Advisory Board (Age 57)
- Prof. Rudolph Emile Tanzi Ph.D., Chief Scientific Advisor and Member of R&D Advisory Board
- Dr. Steven D. Targum M.D., Chief Medical Advisor
How do I buy shares of Prana Biotechnology?
Shares of PRAN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Prana Biotechnology's stock price today?
One share of PRAN stock can currently be purchased for approximately $1.40.
How big of a company is Prana Biotechnology?
Prana Biotechnology has a market capitalization of $11.83 million and generates $150,000.00 in revenue each year. The biotechnology company earns $-6,400,000.00 in net income (profit) each year or ($0.70) on an earnings per share basis. Prana Biotechnology employs 14 workers across the globe.
What is Prana Biotechnology's official website?
How can I contact Prana Biotechnology?
Prana Biotechnology's mailing address is Level 3 460 Bourke Street, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-9349-4906 or via email at [email protected]
MarketBeat Community Rating for Prana Biotechnology (NASDAQ PRAN)
MarketBeat's community ratings are surveys of what our community members think about Prana Biotechnology and other stocks. Vote "Outperform" if you believe PRAN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAN will underperform the S&P 500 over the long term. You may vote once every thirty days.
